NeOnc to Unveil Phase 2a Data for Intranasal NEO100 in Recurrent Glioma
Event summary
- NeOnc Technologies will host an investor call on August 12, 2026 to discuss topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma.
- The open-label study evaluated NEO100™, a proprietary formulation of purified perillyl alcohol, in patients with progressive Grade III and IV gliomas.
- Key topics include efficacy/safety observations and planned regulatory next steps.
- NeOnc’s drug candidates are advancing under FDA Fast-Track and IND status.
The big picture
NeOnc’s focus on overcoming the blood-brain barrier positions it in a niche but growing segment of CNS oncology. The Phase 2a results could validate its proprietary delivery platform, though competition from CAR-T and other targeted therapies looms. Success hinges on demonstrating meaningful efficacy in recurrent gliomas, where treatment options remain limited.
What we're watching
- Regulatory Pathway
- Whether Phase 2a data supports accelerated approval pathways for NEO100 in recurrent glioma.
- Execution Risk
- The pace at which NeOnc can advance NEO100 and NEO212 through late-stage trials given resource constraints.
- Competitive Positioning
- How differentiated intranasal delivery proves against emerging CNS cancer therapies targeting IDH mutations.
Related topics